ArticleInternational journal of medical sciences2021
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in International journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study.Frontiers in oncology · 2025Article
- Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.Cancer cell international · 2024Article
- Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study.BMC cancer · 2024Article
- Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.Cost effectiveness and resource allocation : C/E · 2024Article
- Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.NPJ breast cancer · 2022Article
- Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 17 institutions in 2 countries.
Eriseld KrasniqiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Laura PizzutiDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Maria Rosaria ValerioDepartment of Surgical, Oncological and Oral Sciences, Medical Oncology Unit, University of Palermo, Italy.
Elisabetta CapomollaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Claudio BottiDepartment of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Giuseppe SanguinetiDepartment of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Paolo MarchettiMedical Oncology Unit B, Policlinico Umberto I, Rome, Italy.
Elisabetta AnselmiMedical Oncology Unit, Azienda Ospedaliera Universitaria Sant'Andrea, Rome, Italy.
Silverio TomaoDepartment of Radiological, Oncological and Anatomo-Pathological Sciences, 'Sapienza' University of Rome, Policlinico Umberto I, Rome, Italy.
Antonio GiordanoSbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA.
Corrado FicorellaMedical Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
Katia CannitaMedical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Lorenzo LiviRadiation Oncology Unit and Department of Clinical and Experimental Biomedical Sciences "Mario Serio", Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Icro MeattiniRadiation Oncology Unit and Department of Clinical and Experimental Biomedical Sciences "Mario Serio", Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Maria MauriDivision of Oncology, San Giovanni Addolorata Hospital, Rome, Italy.
Filippo GrecoDepartment of Pathology, Surgery and Oncology, "Mater Salutis" Hospital, ULSS21, Verona, Italy.
Enzo Maria VeltriOncology Unit, S. Maria Goretti Hospital, Latina, Italy.
Andrea MichelottiUO Oncologia Medica I, S. Chiara Hospital, Dipartimento di Oncologia, Dei Trapianti e Delle Nuove Tecnologie, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Luca MoscettiDivision of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
Francesco GiottaDepartment of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.
Vito LorussoDepartment of Medical Oncology, "Giovanni Paolo II" Institute, Bari, Italy.
Ida ParisGynecology Oncology Unit, Catholic University of the Sacred Heart, Rome, Italy.
Federica TomaoDepartment of Gynecology-Obstetrics and Urology, "Sapienza" University of Rome, Rome, Italy.
Daniele SantiniDepartment of Oncology, University Campus Biomedico of Rome, Rome, Italy.
Giuseppe ToniniDepartment of Oncology, University Campus Biomedico of Rome, Rome, Italy.
Alice VillaDepartment of Medical Oncology, Policlinico Universitario "A. Gemelli", Rome, Italy.
Vittorio GebbiaMedical Oncology, La Maddalena Nursing Home, University of Palermo, Palermo, Italy.
Teresa GamucciMedical Oncology Unit, Sandro Pertini Hospital, Rome, Italy.
Gennaro CilibertoScientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Isabella SperdutiBio-Statistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Marco MazzottaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Maddalena BarbaDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Patrizia ViciDivision of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Tumori Bari · ITPoliclinico Umberto I · ITUniversità Campus Bio-Medico · ITAgostino Gemelli University Polyclinic · ITAzienda Ospedaliera Sant'Andrea · ITAzienda Ospedaliero-Universitaria Careggi · ITOspedale Sandro Pertini · ITOspedale Santa Maria Goretti · ITSan Salvatore Hospital · ITSapienza University of Rome · ITTemple University · USUniversità Cattolica del Sacro Cuore · ITUniversity of Florence · ITUniversity of L'Aquila · ITUniversity of Modena and Reggio Emilia · ITUniversity of Palermo · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFemaleFuransHumansKetonesMiddle AgedNeoadjuvant TherapyNeoplasm StagingPolyether PolyketidesProgression-Free SurvivalRetrospective StudiesTriple Negative Breast NeoplasmseribulinFuransKetonesPolyether Polyketideschemotherapyefficacy outcomeseribulin mesylatetoxicity outcomestriple negative metastatic breast cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.